Real-world Data to Generate Evidence About Healthcare Interventions
Open Access
- 4 September 2019
- journal article
- research article
- Published by Springer Nature in Asian Bioethics Review
- Vol. 11 (3) , 289-298
Abstract
It is increasingly recognised that evidence generated using “real-world data” (RWD) is crucial for assessing the safety and effectiveness of health-related interventions. This, however, raises a number of issues, including those related to (1) the quality of RWD, and of the scientific methods used to generate evidence from it, and (2) the potential for those gathering and using RWD be driven by commercial, political, professional or personal self-interest. This article is an application of the framework presented in this issue of ABR (Xafis et al. 2019). Please refer to that article for more information on how this framework is to be used, including a full explanation of the key values involved and the balancing approach used in the case study at the end to demonstrate how those generating or using RWD can make use of values when deliberating about ethical issues.Keywords
This publication has 10 references indexed in Scilit:
- An Ethics Framework for Big Data in Health and ResearchAsian Bioethics Review, 2019
- Government’s vaginal mesh audit does not go far enough, say campaigners2018
- Vaginal mesh procedures need compulsory register, says royal college2018
- Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet TherapyCirculation: Cardiovascular Quality and Outcomes, 2015
- Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?Pharmacoepidemiology and Drug Safety, 2014
- Review of the quality of observational studies of the association between rosiglitazone and acute myocardial infarction.2014
- Oversight and Evidence in Stem Cell Innovation: An Examination of International GuidelinesLaw, Innovation and Technology, 2014
- Postmarketing Safety SurveillanceDrug Safety, 2013
- Revisiting the Rosiglitazone Story — Lessons LearnedNew England Journal of Medicine, 2010
- The Rosiglitazone Story — Lessons from an FDA Advisory Committee MeetingNew England Journal of Medicine, 2007